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Objective To compare time to diagnosis of the typically slow-
growing Type I (low-grade serous, low-grade endometrioid,
mucinous, clear cell) and the more aggressive Type II (high-grade
serous, high-grade endometrioid, undifferentiated,
carcinosarcoma) invasive epithelial ovarian cancer (iEOC).
Design Multicentre observational study.
Setting Ten UK gynaecological oncology centres.
Population Women diagnosed with primary EOC between 2006
and 2008.
Methods Symptom data were collected before diagnosis using
patient questionnaire and primary-care records. We estimated
patient interval (first symptom to presentation) using questionnaire
data and diagnostic interval (presentation to diagnosis) using
primary-care records. We considered the impact of first symptom,
referral and stage on intervals for Type I and Type II iEOC.
Main outcome measures Patient and diagnostic intervals.
Results In all, 78% of 60 Type I and 21% of 134 Type II iEOC were
early-stage. Intervals were comparable and independent of stage
[e.g. median patient interval for Type I: early-stage 0.3 months
(interquartile range 0.3–3.0) versus late-stage 0.3 months
(interquartile range 0.3–4.5), P = 0.8]. Twenty-seven percent of
women with Type I and Type II had diagnostic intervals of at least
9 months. First symptom (questionnaire) was also similar, except
for the infrequent abnormal bleeding (Type I 15% versus Type II
4%, P = 0.01). More women with Type I disease (57% versus 41%,
P = 0.04) had been referred for suspected gynaecological cancer.
Median time from referral to diagnosis was 1.4 months for women
with iEOC referred via a 2-week cancer referral to any specialty
compared with 2.6 months (interquartile range 2.0–3.7) for women
who were referred routinely to gynaecology.
Conclusion Overall, shorter diagnostic delays were seen when a
cancer was suspected, even if the primary tumour site was not
recognised to be ovarian. Despite differences in carcinogenesis and
stage for Type I and Type II iEOC, time to diagnosis and symptoms
were similar. Referral patterns were different, implying subtle
symptom differences. If symptom-based interventions are to impact
on ovarian cancer survival, it is likely to be through reduced volume
rather than stage-shift. Further research on histological subtypes is
needed.
Keywords Delays, early diagnosis, ovarian cancer, symptoms,
Type I and II epithelial ovarian cancer.
Tweetable abstract No difference in time to diagnosis for Type I
versus Type II invasive epithelial ovarian cancers.
Linked article This article is commented on by E Gerry and I-M
Shih, p. 1021 in this issue. To view this mini commentary visit
http://dx.doi.org/10.1111/1471-0528.13502.
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Introduction
Ovarian cancer remains the most lethal gynaecological can-
cer in the UK.1 There is an enduring perception that delays
in presentation and onward referral are the root cause.
Diagnosis relies on symptomatic presentation because pop-
ulation-based screening has yet to show a mortality bene-
fit.2 This has led to major efforts to shorten the time to
diagnosis by raising public awareness of symptoms, encour-
aging women to present earlier, and issuing guidance
encouraging primary-care physicians to investigate women
with a given symptom profile.3–5
Numerous studies6–14 have examined time to ovarian
cancer diagnosis intervals, with median symptom onset to
diagnosis varying from <1 month8 to >12 months.7,12
Common to all the reports is the underlying premise that
ovarian cancer is a single disease entity. This is at odds
with our understanding that ovarian cancer is a heteroge-
neous disease, and that the key to improving outcomes is
focusing on invasive epithelial ovarian cancer (iEOC), par-
ticularly the more aggressive high-grade serous carcino-
mas.15 There is growing consensus that iEOC consists of
five histological subtypes (low-grade serous, clear cell,
endometrioid, mucinous and high-grade serous cancers),
which differ in their underlying biology.
Invasive epithelial ovarian cancer can be grouped broadly
into indolent Type I cancers (comprising low-grade serous,
clear cell, endometrioid, mucinous) that are often diag-
nosed at early stages with more favourable prognosis, and
highly aggressive, rapidly evolving Type II tumours (high-
grade serous and its variants) that are typically diagnosed
at advanced stages and are associated with poor survival.16–
18 Type I tumours are thought to develop in a stepwise
fashion from benign/borderline ovarian neoplasms,19,20
whereas accumulating evidence suggests that Type II can-
cers arise from precursor lesions in the fallopian tubes.18
While type-specific classification is likely to be an oversim-
plification of non high-grade serous histotypes,21,22 it
broadly represents two groups of interest; aggressive, rap-
idly advancing tumours and slow-growing tumours. We
hypothesised that if time to diagnosis rather than biology
was a major contributor to stage at diagnosis, the signifi-
cant stage differences in the two iEOC subtypes should be
accompanied by differences in symptoms and time to diag-
nosis. This is important because many symptom awareness
efforts are underway with little evidence to suggest that a
symptoms-based tool could achieve earlier diagnosis.
This paper aims to provide the first estimates of time-to-
diagnosis intervals for Type I versus Type II iEOC using
two different data sources (patient questionnaires and pri-
mary-care records) in a multicentre setting. We also com-
pare intervals for borderline tumours versus iEOC.
Methods
We obtained the relevant ethics approval from the Joint
University College London/University College Hospital
London Research Ethics Committee (05/Q0505/58). All
participants provided written informed consent and were
enrolled in the UK Ovarian Cancer Population Study
(UKOPS—a biobank case–control study). Recruitment was
from ten centres across England, Wales and Northern
Ireland between February 2006 and February 2008. We
only included women aged ≥45 years with primary EOC
(International Classification of Diseases tenth revision, code
C56) who were recruited before definitive diagnosis or
treatment.
Confirmation of diagnosis
An independent gynaecological oncologist confirmed the
original diagnosis [morphology, grade and International
Federation of Gynecology and Obstetrics (FIGO) stage] by
review of pathology/cytology reports and relevant hospital
records (surgery notes, discharge summaries, multidisci-
plinary team summaries and other correspondence). The
EOC were classified into borderline and invasive EOC. We
grouped the iEOC into Type I (low-grade serous, low/mod-
erate-grade endometrioid, clear cell and mucinous cancers)
and Type II [moderate/high-grade serous, high-grade endo-
metrioid, undifferentiated, malignant mixed mesodermal
(carcinosarcomas)] cancers.22,23 Borderline tumours with
their excellent survival rates, younger age of onset, differing
risk factors and favourable response to surgery were
assessed separately from iEOC. Although borderlines were
included under Type I in the original proposed model,16
the growing consensus has been to exclude them from
analysis of Type I and Type II cancers and restrict the focus
to iEOC.23–25
Symptom ascertainment
Symptom ascertainment has been described previously.26
Briefly, symptom data were collected before diagnosis using
two methods: a self-completed questionnaire (Q) and
review of primary-care records (general practitioner
records; GP). We used a checklist of ovarian cancer symp-
toms (pelvic/abdominal pain or discomfort, increase in
abdominal size, abdominal bloating, abdominal lump, indi-
gestion, diarrhoea, constipation, nausea/vomiting, irregular
vaginal bleeding, urinary frequency or urgency, fatigue, loss
of appetite, weight loss, back pain).
Only symptoms that were new within 15 months
before diagnosis were included in the analysis (to
exclude longstanding symptoms unrelated to the diagno-
sis of cancer). This cut-off was the longest interval, such
that symptoms in cases were more common than in
controls.27
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First symptom
To assess whether first symptom(s) differed by tumour
type, we grouped symptoms into abdominal (pelvic/
abdominal pain or discomfort, increase in abdominal size,
abdominal bloating, abdominal lump), gastrointestinal
(indigestion, diarrhoea, constipation, change in bowel
habit, nausea/vomiting), gynaecological (irregular vaginal
bleeding), urinary (frequency or urgency) or systemic (fati-
gue, weight loss, loss of appetite).
Time intervals
We followed the Aarhus statement28 and used clearly
defined key time-points (see Supplementary material,
Appendix S1). We only used questionnaire data to calculate
patient intervals because symptom-onset dates are rarely
recorded in primary-care records. Similarly, primary-care
records were used to calculate diagnostic intervals because
they contained the most accurate dates for first presenta-
tion.
First referral
We used medical record data (primary-care records, hospi-
tal letters, multidisciplinary team summaries) to identify
the mode and date of first referral. We grouped referrals
into (1) 2-week cancer referral to gynaecological oncology,
(2) 2-week cancer referral to nongynaecological specialties,
(3) routine referral to general gynaecology, (4) routine
referral to nongynaecological specialties, and (5) accident
and emergency (this last group was included because 24%
of cancers in the UK are diagnosed via emergency presenta-
tions).29
Statistical analysis
We hypothesised that if time to diagnosis was a significant
contributor to stage at diagnosis, then time-to-diagnosis
intervals should be different between the biologically dispa-
rate Type I and Type II iEOC. Specifically, we expected
longer time to diagnosis to be associated with more
advanced stage in Type I iEOC, but not in Type II iEOC
(because of aggressive disease/rapid progression). We also
reasoned that women with Type II iEOC would be more
symptomatic and have different referral patterns compared
with Type I iEOC. To examine our hypotheses, we com-
pared time-to-diagnosis intervals and first symptom fre-
quency by tumour type: Type I versus Type II iEOC
subtypes and for borderline tumours versus all invasive
EOC tumours.
We calculated the proportion of women who had patient
and diagnostic intervals of 0 to <3, ≥3 to <6, ≥6 to <9 and
≥9 months for each tumour group. We adjusted patient
intervals to accommodate for missing symptom dates by
multiplying the proportion of women with known symp-
tom dates by the proportion of all women with a
symptom. This seemed reasonable because the proportion
of women with no calculable interval due to missing onset
dates was similar for Type I (77%) and Type II (79%)
iEOC.
To assess if first referral differed according to tumour
type, for each referral mode and tumour type we compared
the proportion of women and the median time from first
referral to diagnosis.
The chi-square test (or Fisher’s exact test when expected
cell frequency was less than five) was used to assess the
relationship between first symptom type and tumour type
(Type I versus II iEOC and borderline versus iEOC). A
stratified Wilcoxon rank sum test30 was used to assess the
relationship between tumour type (Type I versus Type II)
and categorical time intervals, and between total interval
and stage, separately for Type I and Type II tumours. We
assessed the relationship between patient/diagnostic inter-
vals and FIGO stage for Type I and Type II cancers sepa-
rately using the Wilcoxon rank sum test.
All statistical analyses were performed using STATA 12
(StataCorp, College Station, TX, USA). A P-value of <0.05
was considered statistically significant. All statistical tests
were two-sided.
Results
A total of 227 women with newly diagnosed primary EOC
were recruited between 2006 and 2008. Of these women,
194 had invasive EOC and 33 had borderline epithelial
ovarian tumours. In all, 222 (98%) completed question-
naires, primary-care records were received for 199 (88%)
women and for 194 (85%) women we had both. Of the
iEOC, 60 were Type I (six low-grade serous, 13 low-grade
endometrioid, 17 clear cell, 19 mucinous, five low grade
mixed) and 134 were Type II (98 high-grade serous, nine
high-grade endometrioid, three undifferentiated, ten carci-
nosarcoma, one transitional, eight adenocarcinoma, five
high-grade mixed) iEOC.
Table 1 details demographic and clinical details for
women with Type I and Type II iEOC and borderline
tumours. Women across all tumour groups were similar
for age at diagnosis (mean age between 62 and 65 years)
and ethnicity (≥ 95% White). Approximately 90% of
women with Type II iEOC and borderline tumours were
postmenopausal, but only 75% of women with Type I
iEOC were postmenopausal. As expected, a higher propor-
tion (78%) of Type I than Type II (21%) had early stage
(I/II) disease. Among those with borderline tumours, 73%
had early-stage disease.
First symptom
The first symptom reported was similar for Type I and II
cancers with the exception of more irregular vaginal bleed-
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ing (almost all postmenopausal) in Type I (Q: 15% versus
4%, P = 0.01) (see Table 2). Abdominal symptoms were
the most common (Q: Type I 77% and Type II 65%),
whereas gynaecological symptoms were the least common
(Q: Type I 15% and Type II 4%). The reporting of bloating
and increased abdominal size was three to four times
higher on questionnaire than in primary-care records (e.g.
Type II bloating 40% Q versus 9% GP).
Borderline tumours had more urinary frequency/urgency
than iEOC (25% versus 10%, P = 0.04) recorded as their
first symptom in primary-care records and none had sys-
temic symptoms.
Time to diagnosis intervals
Patient and diagnostic intervals were similar for Type I and
Type II iEOC, although a higher proportion of women
with Type I presented within 3 months of symptom onset
(Table 3). Total intervals were also comparable: 6.5 months
(interquartile range 2.8–10.4) for Type I versus 7.2 months
(interquartile range 3.9–12.8) for Type II.
For both Type I and Type II, median patient intervals
were short (within 1 month) and median diagnostic inter-
vals were several months longer than patient intervals (see
Supplementary material, Table S1).
In all, 12.2% of women with Type I and 8.1% with Type
II cancers delayed presentation for ≥ 9 months (Table 3),
and 27% of women with Type I and Type II iEOC had
diagnostic intervals of ≥ 9 months.
There were no significant trends between time-to-diag-
nosis intervals and cancer stage in either Type I or Type II
tumours (Table 3 and see Supplementary material, Fig-
ure S1a,b). Furthermore, 19% (3/16) of women with Type
II had early-stage disease despite long total intervals of at
least 9 months and 43% (3/7) of Type I had late-stage dis-
ease despite having short total intervals (see Supplementary
material, Table S2). However, all intervals were more likely
to be longer in late-stage than in early-stage disease.
Mode of referral
Fourteen women were diagnosed as a result of incidental
findings (six Type I, seven Type II, one borderline) and
referral pathways were unknown for 11 women. In the
remaining women, the most common initial referral across
all tumour types was a 2-week cancer referral to gynaeco-
logical oncology (ranging from 34% for Type II to 60% for
borderline tumours). A higher proportion of women with
Type I versus Type II cancers had a 2-week cancer referral
to gynaecological oncology (P = 0.005), whereas more Type
II women had a routine referral to nongynaecological spe-
cialties (P = 0.17) (Table 4). Higher proportion of border-
line compared with iEOC had a 2-week cancer referral to
gynaecological oncology (P = 0.05); however, numbers
were small.
Time from first referral to diagnosis according to referral
mode was comparable for Type I versus Type II tumours.
Excluding the women who presented as emergencies, time
from referral to diagnosis was typically 1 month longer for
routine referrals both to general gynaecology and nongy-
naecological departments. Following referral, women with
borderline tumours took longer than women with iEOC to
be diagnosed.
Discussion
Main findings
To our knowledge, this is the first study to examine time-
to-diagnosis intervals in iEOC grouped into the molecularly
and clinically distinct Type I and Type II iEOC. Despite
expected large differences in stage distribution, we found
no differences in time-to-diagnosis intervals in women with
Type I compared with Type II iEOC. Symptom profiles
were also broadly comparable for all cancer groups, imply-
ing that symptoms may not reflect underlying tumour
biology and pathogenesis. An exception to this was that
more Type I than Type II cancers had initial symptoms of
Table 1. Demographics and clinical details (n = 227)
Type I iEOC
(n = 60)
Type II iEOC
(n = 134)
Borderline
ovarian tumours
(n = 33)
Age at diagnosis, (years)
Mean (SD) 62.2 (10.7) 65.3 (9.8) 63.9 (12.2)
Range 46–83 46–90 45–87
Ethnicity
White 57 (95%) 130 (97%) 33 (100%)
Other 3 (5%) 4 (3%) 0 (0%)
Menopausal status
Unknown 5 (8%) 1 (1%) –
Perimenopausal 10 (17%) 14 (10%) 3 (9%)
Postmenopausal 45 (75%) 119 (89%) 30 (91%)
Using HRT 9 (20%) 43 (36%) 8 (27%)
Not using HRT 28 (62%) 65 (55%) 21 (70%)
Unknown if
using HRT
8 (18%) 11 (9%) 1 (3%)
FIGO stage
I 42 (70%) 14 (10%) 24 (73%)
II 5 (8%) 14 (10%) 0 (0%)
III 11 (18%) 80 (60%) 3 (9%)
IV 2 (3%) 25 (19%) 0 (0%)
Unstaged – 1 (1%) 6 (18%)
Tumour grade
1 23 (38%) – NA
2 18 (30%) 22 (16%)
3 12 (20%) 91 (68%)
Unknown 7 (12%) 21 (16%)
HRT, hormone replacement therapy.
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irregular vaginal bleeding (a red flag symptom for gynaeco-
logical malignancy). However, this was an infrequent symp-
tom. Despite apparently similar symptom profiles, the
referral patterns were different among tumour groups. The
fact that more women with Type I than Type II iEOC were
first referred for a suspected gynaecological malignancy sug-
gests that there are subtle differences in symptom severity,
frequency or progression that we were unable to disentangle.
Strengths and limitations
A major strength of this study is that we used two differ-
ent sources to collect data on time intervals to ovarian
cancer diagnosis – onset of symptoms directly from
patients, date of first presentation from primary-care
records and date of diagnosis from secondary care histol-
ogy records. Using this approach, the high sensitivity of
each source for a particular data item was maximised. To
truly combine the data into a single interval from symp-
tom onset to diagnosis requires a complex algorithm which
we are currently developing. Other strengths include the
multicentre design involving ten gynaecological oncology
centres across the UK, thereby providing a more represen-
tative sample.
It is possible that subtle differences between clear cell and
endometrioid tumours have been masked by our Type I/II
grouping.31 Nevertheless, we feel that within the context of
the aims of our study (to estimate time to diagnosis accord-
ing to a broad dichotomy of aggressive, rapidly advancing
cancers versus indolent cancers with favourable prognoses)
our chosen grouping would have minimal impact on the
outcomes of interest. A gynaecological oncologist reviewed
all pathology and related records and confirmed diagnosis.
Central pathological review was not undertaken before this
analysis. Although there is evidence of discordance in histo-
Table 2. Nature of first symptom by tumour group
Questionnaire GP notes Questionnaire GP notes
Type I iEOC
(n = 57)
Type II iEOC
(n = 132)
Type I iEOC
(n = 54)
Type II iEOC
(n = 117)
iEOC
(n = 189)
Borderline
(n = 33)
iEOC
(n = 171)
Borderline
(n = 28)
Women with symptom n = 53 n = 124 n = 48 n = 110 (n = 177) (n = 26) (n = 158) (n = 24)
Abdominal
≥1 abdominal
first symptom
41 (77%) 80 (65%) 23 (48%) 51 (46%) 121 (68%) 20 (77%) 74 (47%) 10 (42%)
Pelvic/abdominal
pain/discomfort
21 (40%) 40 (32%) 14 (29%) 31 (28%) 61 (34%) 8 (31%) 45 (28%) 6 (25%)
Increase in abdominal size 23 (43%) 43 (35%) 8 (17%) 11 (10%) 66 (37%) 11 (42%) 19 (12%) 3 (13%)
Abdomen feels bloated 22 (42%) 49 (40%) 5 (10%) 10 (9%) 71 (40%) 13 (50%) 15 (9%) 0 (0%)
Able to feel a lump in
abdomen
5 (9%) 9 (7%) 2 (4%) 6 (5%) 14 (8%) 4 (15%) 8 (5%) 3 (13%)
Gastrointestinal (GI)
≥1 GI first symptom 16 (30%) 42 (34%) 14 (29%) 36 (33%) 58 (33%) 5 (19%) 50 (32%) 5 (21%)
Indigestion 5 (9%) 21 (17%) 4 (8%) 11 (10%) 26 (15%) 3 (12%) 15 (9%) 1 (4%)
Constipation 7 (13%) 19 (15%) 4 (8%) 8 (7%) 26 (15%) 2 (8%) 12 (8%) 2 (8%)
Diarrhoea 2 (4%) 11 (9%) 1 (2%) 4 (4%) 13 (7%) 2 (8%) 5 (3%) 1 (4%)
Change in bowel habit 1 (2%) 1 (1%) 1 (2%) 10 (9%) 2 (1%) 0 (0%) 11 (7%) 2 (8%)
Nausea or vomiting 8 (15%) 8 (6%) 5 (10%) 7 (6%) 16 (9%) 2 (8%) 12 (8%) 0 (0%)
Gynaecological
Irregular vaginal bleeding 8 (15%) 5 (4%)* 6 (13%) 4 (4%)* 13 (7%) 1 (4%) 10 (6%) 2 (8%)
Urinary
Urinary frequency or urgency 9 (17%) 17 (14%) 8 (17%) 8 (15%) 26 (15%) 8 (31%) 16 (10%) 6 (25%)*
Systemic
≥1 systemic first symptom 20 (38%) 54 (44%) 5 (10%) 17 (15%) 74 (42%) 6 (23%) 22 (14%) 0 (0%)*
Loss of appetite 6 (11%) 20 (16%) 0 (0%) 5 (5%) 26 (15%) 2 (8%) 5 (3%) 0 (0%)*
Weight loss 10 (19%) 17 (14%) 1 (2%) 7 (6%) 27 (15%) 1 (4%) 8 (5%) 0 (0%)*
Fatigue 11 (21%) 34 (27%) 4 (4%) 10 (9%) 45 (25%) 4 (15%) 14 (9%) 0 (0%)*
Other
Back pain 4 (8%) 13 (10%) 3 (6%) 13 (12%) 17 (10%) 2 (8%) 16 (10%) 2 (8%)
Women may have more than one-first symptom type. Percentages are calculated with the number of women who reported a (new checklist)
symptom on each source as the denominator.
*P < 0.05.
1016 ª 2015 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists.
Lim et al.
logical subtyping between local and expert review, this relates
to reclassification of high-grade endometrioid, high-grade
mixed and undifferentiated into high-grade serous.32 This
was anticipated when we undertook our classification into
Type I and Type II disease and therefore does not affect our
analysis. Although women were systematically approached,
selection bias was inevitable in common with all studies
based on individual consent. Another limitation was that
patient interval data were based on retrospective report,
which can give rise to recall bias and recall error. Although
for any systematic errors in symptom reporting (i.e. recall
bias), the bias would have been the same for our main com-
parator groups because women did not know if they had
Type I or Type II iEOC at the time of questionnaire comple-
tion. In addition, women may not have recalled symptom
details accurately because of memory decay (recall error).
This could have resulted in overestimation or underestima-
tion of patient intervals. We minimised this by collecting
questionnaire data at or before definitive diagnosis. Small
numbers in subgroups limited some of our assessments.
Finally, six of the women in the current analysis were
enrolled in the control (no intervention) arm of the UK Col-
laborative Trial of Ovarian Cancer Screening (UKCTOCS). It
is possible that these women were more health aware but
given that the healthy volunteer effect decreases with time
from randomisation,33 it is of note that recruitment to UKC-
TOCS was completed in 2005 and the above six women were
diagnosed between 2006 and 2008.
Interpretation
Our patient and diagnostic intervals are comparable to
those previously reported (medians between 1 and
4 months).10,12,14,34 Also in corroboration of our findings,
a large population-based case–control study in Australia
reported no difference in time-to-diagnosis intervals for
early- versus late-stage iEOC.6 We are only aware of one
other study35 that examined time to diagnosis of EOC by
histological subtype. They found that women with serous
ovarian cancer had longer mean patient intervals compared
with other histological types of epithelial ovarian cancer
(12 weeks versus 7 weeks, P < 0.05).
The short median patient intervals in our study belie the
fact that one in five women with iEOC reported having
symptoms for at least 6 months before presenting.
Recently, an International Cancer Benchmarking Partner-
ship study identified increased perceived barriers to symp-
tomatic presentation in the UK compared with similar
European countries, especially concern about wasting the
doctor’s time.36 Despite the recruitment period being
2006–08, there were considerable delays in diagnosis with
one in four women with iEOC (whether Type I or II)
experiencing diagnostic intervals of ≥ 9 months. Most
women were not referred appropriately, only 41% with
iEOC were initially referred to gynaecological oncology.
Nevertheless, time from referral to diagnosis was similar
for all 2-week cancer referrals, indicating that suspecting
malignancy is more important than diagnosing the correct
cancer site. This most likely reflects the reorganisation of
cancer services in the National Health Service in the UK,
which ensures multidisciplinary review of all new cases in a
timely manner with strict standards on time to treatment
from primary-care referral.
If time to diagnosis was a significant contributor to stage
at diagnosis, then patient and diagnostic intervals should
be different between the biologically disparate Type I and
Type II iEOC. Instead it seems that the link between symp-
toms and tumour biology in ovarian cancer is complex and
that a symptom-based intervention may not result in ear-
lier stage diagnosis of Type II iEOC.
The fact that upper quartiles for late stage intervals tended
to be longer than for early stage indicated a bimodal distribu-
tion for late stage: either short because of very aggressive dis-
ease or long leading to advanced disease. Our findings are in
Table 3. Patient and diagnostic intervals (months) for Type I and II
tumours and according to early versus late stage
Type I iEOC Type II iEOC
Patient interval (n = 57) (n = 132)
No. with symptom 53 124
No. with interval 41 98
0 to < 3 m* 29 (70.1%) 64 (51.6%)
3 to < 6 m* 2 (4.8%) 17 (13.7%)
6 to < 9 m* 5 (12.2%) 7 (5.6%)
≥ 9 m* 5 (12.2%) 10 (8.1%)
Median months (IQR)
Early stage 0.3 (0.3–3.0) n = 33 1.0 (0.3–4.0) n = 18
Late stage 0.3 (0.3–4.5) n = 8 1.8 (0.3–5.0) n = 79
Diagnostic
interval
(n = 54) (n = 117)
No. with
symptom
48 110
No. with
interval
48 110
0 to <3 m 23 (47.9%) 44 (40.0%)
3 to <6 m 10 (20.8%) 29 (26.4%)
6 to < 9 m 2 (4.2%) 7 (6.4%)
≥9 m 13 (27.1%) 30 (27.3%)
Median months (IQR)
Early stage 3.0 (2.0–6.1) n = 37 3.5 (2.2–6.4) n = 24
Late stage 3.7 (1.3–12.8) n = 11 4.1 (1.7–9.8) n = 86
IQR, interquartile range.
*Adjusted by multiplying number of women in interval by proportion
of women with symptoms who had an estimable interval.
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keeping with emerging data on the natural history of high-
grade serous iEOC where modelling suggests that early in the
course of disease at a median diameter of about 3 cm, serous
ovarian cancers progress to an advanced stage (stage III or
IV).37 This suggests that in Type II iEOC a symptom-based
intervention is more likely to influence tumour volume than
impact on stage. This is supported by the recent prospective
study (DOvE study; Diagnosing Ovarian Cancer Early)38
where CA125 testing and transvaginal ultrasound in women
with ovarian cancer symptoms resulted in detection of lower
volume disease in women with high-grade serous ovarian
cancers.39 Diagnosis at lower tumour volumes is likely to
improve the surgeon’s ability to achieve zero residual disease
at surgery, a key prognostic factor in disease survival.40 In
addition, less intra-tumour heterogeneity may lead to a bet-
ter response to chemotherapy.
The drive by service providers and patients to raise
symptom awareness and introduce systematic CA125 and
ultrasound testing in primary care is understandable given
the continued significant delays in diagnosis. In our study,
one in four women had diagnostic intervals >9 months.
However, given the prevalence and non-specific nature of
symptoms41 the significant resource implications and
potential harm to symptomatic women without ovarian
cancer,42 it remains controversial as to whether or not cur-
rent evidence is adequate to support practice change or a
prospective randomised controlled trial of a symptom-
based intervention is needed to comprehensively assess
impact.
Conclusion
Overall, shorter diagnostic delays were seen when a cancer
was suspected, even if the primary tumour site was not
recognised to be ovarian. Despite differences in tumour
biology, carcinogenesis and stage at diagnosis, no difference
in time to diagnosis for Type I and II ovarian cancers was
noted. However, the pattern of referral was different,
implying that there may be subtle differences in symptoms.
If symptom-based interventions impact on survival, it is
unlikely to be through stage shift. Further research focused
on histological subtypes is needed.
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**One woman had a routine referral to clinical oncology as she was still undergoing follow up for colon cancer.
1018 ª 2015 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists.
Lim et al.
provided statistical support for the analysis. PS and UM
supervised the interpretation of the analysis, and revised the
manuscript. AWL, PS and UM had full access to all of the
data in the study and take responsibility for the integrity of
the data and the accuracy of the data analysis as well as the
final decision to submit for publication. MW confirmed his-
tological diagnosis. IJ contributed to the main study design
and reviewed the final manuscript. All authors accept
responsibility for the paper as published.
Details of ethics approval
Ethics approval was obtained from the Joint University
College London/University College Hospital London
Research Ethics Committee (05/Q0505/58) on 29 July 2005.
Funding
This study was funded by Cancer Research UK (C8162/
A6138 to PS and AWL and C8162/A10406 to PS and DM);
Eve Appeal/Oak Foundation (to UM and IJ) and was sup-
ported by researchers at the National Institute for Health
Research University College London Hospitals Biomedical
Research Centre.
Acknowledgements
We thank all the women who took part in this study,
the UK Ovarian Cancer Population Study lead investiga-
tors and research nurses at each of the participating
centres, Prof. Simon Gather, and Dr Andy Ryan at the
United Kingdom Ovarian Cancer Population Study Coor-
dinating Centre at University College London (London,
UK), and the late Prof. Joan Austoker and Dr Clare
Bankhead, University Research Lecturer (Department of
Primary Health Care Sciences, University of Oxford,
Oxford, UK). The United Kingdom Ovarian Cancer Pop-
ulation Study was carried out by the University College
London Hospital/University College London within the
‘women’s health theme’ of the National Institute for
Health Research University College London Hospital/
University College London Comprehensive Biomedical
Research Centre supported by the Department of Health
(London, UK).
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. (a) Time from first symptom to presentation
by stage at diagnosis and by tumour type—cumulative pro-
portion of women.
Table S1. Time to diagnosis intervals (months) by
tumour type.
Table S2. Total intervals (months) for early versus late
stage Type I and Type II tumours.
Appendix S1. Supplementary methods.&
References
1 Office for National Statistics. Cancer Incidence and Mortality in the
United Kingdom, 2008–10. London: Office for National Statistics,
2012.
2 Moyer VA. Screening for ovarian cancer: U.S. Preventive Services
Task Force reaffirmation recommendation statement. Ann Intern
Med 2012;157:900–4.
3 Department of Health. Ovarian cancer: key messages for health
professionals. 2009 [www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH_110534]. Accessed
4 February 2011.
4 Gynecologic Cancer Foundation SoGO, and American Cancer
Society. Ovarian cancer symptoms consensus statement. 2007
[www.wcn.org/ov_cancer_cons.html]. Accessed 11 May 2011.
5 National Institute for Health and Clinical Excellence. Ovarian Cancer:
The Recognition and Initial Management of Ovarian Cancer. Clinical
guidelines CG122. London: NICE, 2011.
6 Nagle CM, Francis JE, Nelson AE, Zorbas H, Luxford K, de Fazio A,
et al. Reducing time to diagnosis does not improve outcomes for
women with symptomatic ovarian cancer: a report from the
Australian Ovarian Cancer Study Group. J Clin Oncol 2011;29:
2253–8.
7 Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S,
Clements A, et al. Identifying symptoms of ovarian cancer: a
qualitative and quantitative study. BJOG 2008;115:1008–14.
8 Chan YM, Ng TY, Lee PW, Ngan HY, Wong LC. Symptoms, coping
strategies, and timing of presentations in patients with newly
diagnosed ovarian cancer. Gynecol Oncol 2003;90:651–6.
9 Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur
J Obstet Gynecol Reprod Biol 1988;27:53–7.
10 Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma
diagnosis. Cancer 2000;89:2068–75.
11 Smith EM, Anderson B. The effects of symptoms and delay in
seeking diagnosis on stage of disease at diagnosis among women
with cancers of the ovary. Cancer 1985;56:2727–32.
12 Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization
of prediagnostic symptoms among primary epithelial ovarian cancer
cases and controls. Gynecol Oncol 2003;90:75–82.
13 Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types
and duration of symptoms prior to diagnosis of invasive or
borderline ovarian tumor. Gynecol Oncol 2001;83:466–71.
14 Webb PM, Purdie DM, Grover S, Jordan S, Dick ML, Green AC.
Symptoms and diagnosis of borderline, early and advanced epithelial
ovarian cancer. Gynecol Oncol 2004;92:232–9.
15 Burger RA. A new model of ovarian carcinogenesis may influence
early detection strategies. Am J Obstet Gynecol 2008;198:349–50.
16 Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model
based on morphological and molecular genetic analysis. Am J Pathol
2004;164:1511–8.
17 Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih I-M. Diverse
tumorigenic pathways in ovarian serous carcinoma. Am J Pathol
2002;160:1223–8.
18 Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial
ovarian cancer: a proposed unifying theory. Am J Surg Pathol
2010;34:433–43.
1019ª 2015 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists.
Time to diagnosis of Type I and II epithelial ovarian cancer
19 Horiuchi A, Itoh K, Shimizu M, Nakai I, Yamazaki T, Kimura K, et al.
Toward understanding the natural history of ovarian carcinoma
development: a clinicopathological approach. Gynecol Oncol
2003;88:309–17.
20 Rodriguez IM, Prat J. Mucinous tumors of the ovary: a
clinicopathologic analysis of 75 borderline tumors (of intestinal type)
and carcinomas. Am J Surg Pathol 2002;26:139–52.
21 Prat J. New insights into ovarian cancer pathology. Ann Oncol
2012;23(Suppl 10):x111–7.
22 Gurung A, Hung T, Morin J, Gilks CB. Molecular abnormalities in
ovarian carcinoma: clinical, morphological and therapeutic
correlates. Histopathology 2013;62:59–70.
23 Prahm KP, Karlsen MA, Høgdall E, Scheller NM, Lundvall L,
Nedergaard L, et al. The prognostic value of dividing epithelial
ovarian cancer into type I and type II tumors based on pathologic
characteristics. Gynecol Oncol 2014;136:205–11.
24 Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C.
Role of histological type on surgical outcome and survival
following radical primary tumour debulking of epithelial ovarian,
fallopian tube and peritoneal cancers. Br J Cancer 2011;105:1818–24.
25 Panici PB, Marchetti C, Salerno L, Musella A, Vertechy L, Palaia I, et al.
Dualistic classification of epithelial ovarian cancer: surgical and survival
outcomes in a large retrospective series. Ann Surg Oncol 2014;21:
3036–41.
26 Lim AWW, Mesher D, Gentry-Maharaj A, Balogun N, Jacobs I,
Menon U, et al. Predictive value of symptoms for ovarian cancer:
comparison of symptoms reported by questionnaire, interview, and
general practitioner notes. J Natl Cancer Inst 2012;104:114–24.
27 Lim AWW. Investigating the potential for expediting ovarian
cancer diagnosis via prompt symptom recognition and ‘targeted
screening’ [PhD thesis]. London: Queen Mary University of London,
2009.
28 Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al.
The Aarhus statement: improving design and reporting of studies on
early cancer diagnosis. Br J Cancer 2012;106:1262–7.
29 Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S,
et al. Routes to diagnosis for cancer – determining the patient
journey using multiple routine data sets. Br J Cancer 2012;107:
1220–6.
30 Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;4:87–90.
31 Prat J. Ovarian carcinomas: five distinct diseases with different
origins, genetic alterations, and clinicopathological features.
Virchows Arch 2012;460:237–49.
32 Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L,
et al. Biomarker-based ovarian carcinoma typing: a histologic
investigation in the ovarian tumor tissue analysis consortium. Cancer
Epidemiol Biomarkers Prev 2013;22:1677–86.
33 Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J,
et al. Impact on mortality and cancer incidence rates of using random
invitation from population registers for recruitment to trials. Trials
2011;12:61.
34 Thulesius HO, Lindgren AC, Olsson HL, Hakansson A. Diagnosis and
prognosis of breast and ovarian cancer–a population-based study of
234 women. Acta Oncol 2004;43:175–81.
35 Wikborn C, Pettersson F, Moberg PJ. Delay in diagnosis of epithelial
ovarian cancer. Int J Gynaecol Obstet 1996;52:263–7.
36 Forbes LJ, Simon AE, Warburton F, Boniface D, Brain KE, Dessaix A,
et al. Differences in cancer awareness and beliefs between Australia,
Canada, Denmark, Norway, Sweden and the UK (the International
Cancer Benchmarking Partnership): do they contribute to differences
in cancer survival? Br J Cancer 2013;108:292–300.
37 Brown PO, Palmer C. The preclinical natural history of serous
ovarian cancer: defining the target for early detection. PLoS Med
2009;6:e1000114.
38 Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, et al.
Assessment of symptomatic women for early diagnosis of ovarian
cancer: results from the prospective DOvE pilot project. Lancet
Oncol 2012;13:285–91.
39 Gentry-Maharaj A, Kalsi J, Burnell M, Manchanda R, Menon U.
Screening of symptomatic women for ovarian cancer. Lancet Oncol
2012;13:e138–9.
40 Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for
advanced-stage ovarian cancer: redefining ‘optimal’ residual disease.
Gynecol Oncol 2012;125:483–92.
41 Low EL, Simon AE, Waller J, Wardle J, Menon U. Experience of
symptoms indicative of gynaecological cancers in UK women. Br J
Cancer 2013;109:882–7.
42 Tone AA, Huntsman DG, Miller DM. Screening of symptomatic
women for ovarian cancer. Lancet Oncol 2012;13:e137–8.
1020 ª 2015 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists.
Lim et al.
